Table 1.
GRADE evidence profile of incretin based treatment and all cause mortality in randomised controlled trials in patients with type 2 diabetes
| Quality assessment | Summary of findings | Quality of evidence | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of participants (studies), follow-up time | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Study event rates | OR (95% CI) | Anticipated absolute effects (5 year time frame) | ||||
| With control | With incretin | Risk with control | Risk difference with incretin (95% CI) | |||||||||
| 151 614 (189), 12-234 weeks | No serious limitations | Serious limitations* | No serious limitations | No serious limitations | Undetected | 1963/67 478 (2.9%) | 1925/84 136 (2.3%) | 0.96 (0.90 to 1.02) | 71 per 1000† | 3 fewer (7 fewer to 1 more) | ⊕⊕⊕ Moderate | |
*Effects might differ in GLP-1 agonists v DPP-4 inhibitors.
†Baseline risk estimate for death in 5 year time frame comes from control arm of one large cohort study we identified to best represent our target population,16 with 948 events of death in 31 950 patients (29.7/1000) over median of 2.1 years’ follow-up period in control arm.